Aclarion, Inc. announced it will participate in the 38th Annual ROTH Conference from March 22-24, 2026, in Dana Point, California. During the conference, CEO Brent Ness will meet with institutional investors and analysts to discuss the company's progress with Nociscan, its proprietary magnetic resonance spectroscopy platform designed to help physicians identify painful discs in patients suffering from chronic low back pain. The company's participation in this prominent investment conference underscores the growing importance of its technology in addressing a significant healthcare challenge.
Chronic low back pain affects millions of people worldwide, and accurately identifying the source of pain has historically been difficult for physicians. Nociscan represents a novel approach that combines biomarkers with augmented intelligence algorithms to provide clearer diagnostic information. CEO Brent Ness stated, "We look forward to engaging with the investment community at ROTH to share the progress we are making and the important catalysts ahead for Aclarion. With a strong balance sheet, no debt, and a focused strategy to expand adoption of Nociscan in both the UK and US, we believe we are well positioned to execute on the significant opportunity ahead."
The Nociscan platform operates as a Software-as-a-Service (SaaS) solution that receives magnetic resonance spectroscopy data from MRI machines for each lumbar disc being evaluated. Proprietary signal processing techniques extract and quantify chemical biomarkers associated with disc pain, which are then analyzed by algorithms to indicate whether a disc may be a source of pain. This technology provides physicians with additional diagnostic information that can help optimize treatment strategies for patients suffering from chronic low back pain. For more information about the company, please visit https://www.aclarion.com. The latest news and updates relating to Aclarion are available in the company's newsroom at https://tinyurl.com/aconnewsroom.
The company's presentation at the ROTH Conference comes as it continues to advance its clinical and commercial initiatives. Aclarion's technology represents a potentially significant advancement in the diagnosis and treatment of chronic low back pain, a condition that has traditionally been challenging to diagnose accurately and treat effectively. The company's strong financial position, with no debt and a solid balance sheet, provides it with resources to pursue its expansion plans in key markets. This development matters because it highlights a technological solution to a pervasive medical problem that impacts quality of life and healthcare costs globally, potentially leading to more targeted and effective treatments for chronic back pain sufferers.
